Homotypic-Targeted Mineralized Tumor Cell Probes for Ultrasensitive MRI Diagnosis of Early-Stage Malignancies

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Medical Imaging

Background:

• Clinically used MRI contrast agents (CAs) have limited selectivity and sensitivity for tumor diagnosis.
• There is a need for advanced contrast agents with improved targeting and signal amplification.

Purpose of the Study:

• To develop novel inactivated cell-based contrast agents (Mn-CCs) for enhanced MRI tumor detection.
• To evaluate the performance of Mn-CCs in terms of targeting, signal activation, and diagnostic accuracy.

Main Methods:

• Constructed mineralized tumor cells (Mn-CCs) using glioma and pancreatic tumor cell templates.
• Assessed Mn-CCs' MRI signal properties under tumor microenvironment (TME) conditions.
• Evaluated in vivo MRI contrast enhancement and tumor detection capabilities in preclinical models.

Main Results:

• Mn-CCs demonstrated homotypic targeting and TME-activated MRI signals.
• Achieved significantly increased longitudinal relaxation rates under TME conditions.
• Mn-CCs showed superior MRI contrast enhancement in glioma and specific detection of small pancreatic tumors, outperforming Gd-DOTA.

Conclusions:

• Mn-CCs represent a promising biomimetic approach for developing sensitive and specific MRI contrast agents.
• These agents offer potential for improved early-stage tumor diagnosis and differentiation.
• The study highlights a novel strategy for designing advanced contrast agents with enhanced biosafety and efficacy.